Immunocore gets EU nod for TCR cancer therapy Kimmtrak
pharmaphorum
APRIL 5, 2022
Immunocore now has approval on both side of the Atlantic for Kimmtrak – the first cancer therapeutic based on T cell receptor (TCR) technology – after getting a green light from the European Commission. GlobalData analyst Dr Sakis Palioras said in a recent research not that Kimmtrak’s 5.7
52 
Let's personalize your content